A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors

First-line therapy for most pediatric sarcoma is based on chemotherapy in combination with radiotherapy and surgery. A significant number of patients experience drug resistance and development of relapsed tumors. Drugs that have the potential to re-sensitize relapsed tumor cells toward chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzella, Gabriele, Moonamale, Devmini C., Römmele, Michaela, Bode, Peter, Wachtel, Marco, Schäfer, Beat W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329430/
https://www.ncbi.nlm.nih.gov/pubmed/34329950
http://dx.doi.org/10.1016/j.neo.2021.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329430/
https://www.ncbi.nlm.nih.gov/pubmed/34329950
http://dx.doi.org/10.1016/j.neo.2021.07.001

Ejemplares similares